share_log

Guggenheim Maintains Buy on Prime Medicine, Lowers Price Target to $20

Guggenheim Maintains Buy on Prime Medicine, Lowers Price Target to $20

古根海姆维持对Prime Medicine的买入,将目标股价下调至20美元
Moomoo 24/7 ·  03/05 12:04

Guggenheim analyst Debjit Chattopadhyay maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $24 to $20.

古根海姆分析师黛布吉特·查托帕迪亚维持Prime Medicine(纳斯达克股票代码:PRME)的买入并将目标股价从24美元下调至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发